 |
96 Diseases |  |
29 Trials |
|
29 Trials |  |
1185 News |  |
| 12345678910111213...1516» |
- || lomustine / Generic mfg., Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer
Clinical, Journal: Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study. (Pubmed Central) - Jan 12, 2025
Regorafenib shows good efficacy and safety as a third-line treatment for recurrent glioblastoma after bevacizumab-based therapy. This study supports the use of regorafenib and emphasizes the need for further randomized studies to validate its role and optimize treatment strategies.
- | Journal: Cyclophosphamide is not associated with clinically relevant late pulmonary dysfunction in Dutch survivors of childhood cancer - the DCCSS-LATER 2 PULM sub-study. (Pubmed Central) - Jan 12, 2025
This study supports the use of regorafenib and emphasizes the need for further randomized studies to validate its role and optimize treatment strategies. This study suggests that cyclophosphamide is not associated with clinically relevant pulmonary dysfunction in long-term childhood cancer survivors.
- | lomustine / Generic mfg.
Journal: Multiple cutaneous mast cell tumors displaying epitheliotropism in a male cat. (Pubmed Central) - Jan 12, 2025
Tumor progression was noted 13 wk later, at which time the cat was treated with lomustine...Toceranib should be considered as an initial treatment for these tumors. Further research is needed to determine the prognosis for cats with epitheliotropic mast cell tumors.
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial suspension: Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Jan 7, 2025
P2, N=184, Suspended, Sponsor: National Cancer Institute (NCI)
Further research is needed to determine the prognosis for cats with epitheliotropic mast cell tumors. Recruiting --> Suspended
- | Journal: Impact of upfront adjuvant chemoradiation on survival in patients with molecularly defined oligodendroglioma: the benefits of PCV over TMZ. (Pubmed Central) - Jan 3, 2025
Adjuvant radiation and PCV are associated with improved PFS over radiation with TMZ in patients with grade 3 molecularly defined oligodendrogliomas, and all-grade patients treated with PCV trended towards decreased risk of recurrence and progression. These results highlight the importance of ongoing clinical trials investigating these treatments.
- | Journal: Clofazimine enhances anti-glioma effect of immunotherapy. (Pubmed Central) - Dec 21, 2024
These results highlight the importance of ongoing clinical trials investigating these treatments. Combination of clofazimine and immunotherapy enhances anti-glioma effect of TMZ in an in vivo model experiment.
- || Clinical, Retrospective data, Review, Journal: protein kinase inhibitors as Targeted therapy for glioblastoma: A meta-analysis of randomized controlled clinical trials. (Pubmed Central) - Dec 6, 2024
Upon disease progression, the anti-vascular endothelial growth factor-A (VEGF-A) monoclonal antibody bevacizumab, can be considered...For instance, when comparing PKI treatment with other treatments, median OS and PFS showed no significant difference (-0.78 months, 95% CI, -2.12-0.55, p=0.25; -0.23 months, 95% CI, -0.79-0.34, p=0.43, respectively), and similar non-significant results were observed in the pooled analyses (OS: HR=0.89, 95% CI, 0.59-1.32, p=0.55; PFS: HR=0.83, 95% CI, 0.63-1.11, p=0.21). Despite these overall negative findings, some data indicate improved clinical outcomes in a subset of GBM patients treated with certain PKIs (i.e., regorafenib) and encourage further research to identify PKIs with better blood-brain barrier penetration and lower risk for resistance development.
- | Opdivo (nivolumab) / BMS
Journal, PD(L)-1 Biomarker, IO biomarker: Long-term survival in a patient with Li-Fraumeni syndrome-associated giant cell glioblastoma treated with nivolumab: illustrative case. (Pubmed Central) - Nov 25, 2024
This case highlights the potential of immunotherapy with PD-L1 checkpoint inhibition in improving outcomes for LFS-associated GBM patients. https://thejns.org/doi/10.3171/CASE24539.
- paxalisib (GDC-0084) / Kazia, SoVarGen, QIMR Berghofer Medical Research Institute
EVALUATION OF PAXALISIB IN GBM AGILE PHASE 3 REGISTRATION PLATFORM TRIAL FOR NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA (Hall A3) - Nov 22, 2024 - Abstract #SNO2024SNO_1794;
P2/3
CONCLUSION Paxalisib did not show survival benefit over cumulative control in final primary analysis; additional secondary analyses are being considered. GBM AGILE continues to rapidly and efficiently assess therapies in ND and RD glioblastoma.
- eflornithine / Orbus Therap
PHASE 3 STELLAR STUDY SHOWS EFLORNITHINE IMPROVES OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) IN PATIENTS WITH RECURRENT 2021 WHO ASTROCYTOMA, IDH-MUTANT GRADE 3 (Hall A3) - Nov 22, 2024 - Abstract #SNO2024SNO_1793;
70, no imaging findings consistent with grade 4 glioblastoma...CONCLUSION There was no difference in OS between arms in the ITT analysis. However, medically meaningful and statistically significant OS and PFS benefits were observed with eflornithine in the pre-planned analysis of patients with molecularly defined 2021 WHO CNS grade 3 astrocytoma.
- | lomustine / Generic mfg., busulfan / Generic mfg.
Journal: Experimental and computational studies on possibility of using glucose diazacrown cryptand as a carrier for anticancer drugs busulfan and lomustine. (Pubmed Central) - Nov 19, 2024
Interestingly, while the cytotoxicity of the L1:BSF complex is stronger than that of pure BSF, the relationship is opposite in the case of L1:CCNU and CCNU. Therefore, L1 can be considered as a potential drug carrier, especially for those drugs that have weak activity on cancer cells.
- | lomustine / Generic mfg., temozolomide / Generic mfg.
Trial initiation date, Combination therapy: Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma (clinicaltrials.gov) - Nov 19, 2024
P3, N=200, Not yet recruiting, Sponsor: Vastra Gotaland Region
Therefore, L1 can be considered as a potential drug carrier, especially for those drugs that have weak activity on cancer cells. Initiation date: May 2024 --> Dec 2024
- | Journal: Impact of 10% Dose Reductions and Duration of Treatment Delays in the Management of Chemotherapy-Induced Neutropenia in Dogs Treated With Common Chemotherapy Protocols: A Single-Centre Experience. (Pubmed Central) - Nov 13, 2024
DR failure occurred in 22/39 (56.4%, 95% CI: 40.9%-70.6%) lomustine DRs, 14/27 (51.9%, 95% CI: 33.9%-69.2%) cyclophosphamide DRs, but only 2/22 (9.1%, 95% CI: 2.5%-27.8%) doxorubicin DRs and 2/24 (8.3%, 95% CI: 2.3%-25.8%) vincristine DRs. Seventy-three evaluable TDs (mean: 5?days, SD?
- | temozolomide / Generic mfg.
Journal: Aggressive pituitary tumors and carcinomas: medical treatment beyond temozolomide. (Pubmed Central) - Nov 13, 2024
Further studies, as well as an individualized, patient-tailored approach, are clearly needed. In addition, we report an unpublished case of a silent corticotroph pituitary carcinoma that progressed under dual immunotherapy, and then showed stable disease under a combination of lomustine and bevacizumab.
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Trial initiation date: Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Nov 13, 2024
P2, N=184, Recruiting, Sponsor: National Cancer Institute (NCI)
In addition, we report an unpublished case of a silent corticotroph pituitary carcinoma that progressed under dual immunotherapy, and then showed stable disease under a combination of lomustine and bevacizumab. Initiation date: May 2025 --> Nov 2024
- ||| galunisertib (LY2157299) / Eli Lilly
Trial completion, Combination therapy, Monotherapy: A Dose-Escalation Study in Participants With Recurrent Malignant Glioma (clinicaltrials.gov) - Nov 7, 2024
P1, N=66, Completed, Sponsor: Eli Lilly and Company
Initiation date: May 2025 --> Nov 2024 Active, not recruiting --> Completed
- Elrexfio (elranatamab-bcmm) / Pfizer, Actemra IV (tocilizumab) / Roche, JW Pharma, Tecvayli (teclistamab-cqyv) / Genmab, J&J
Debulking Conventional Chemotherapy before Treatment By Anti-BCMA Bispecific Antibody in Extramedullary and/or High Tumor Burden Relapsed/Refractory Multiple Myeloma (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_5611;
Regarding debulking chemotherapy, 92% (n=33) received alkylating agents, including cyclophosphamide (89%, n=32) and belustine (14%, n=5), 42% (n=15) received anthracyclines, 56% (n=20) received etoposide, 11% (n=4) received vincristine, and 14% (n=5) received cisplatin...Teclistamab was used in 29 patients (81%) and elranatamab in 7 patients (19%) with a median interval between chemotherapy and BsAb administration of 36 days (range : 4-197)...Tocilizumab was used in 7 patients (19%) and dexamethasone in 4 patients (11%)...We reported a high response rate and a PFS comparable to the overall population receiving BsAb. This strategy can be used in a challenging population to improve response to novel immunotherapy.
- | lomustine / Generic mfg.
Journal: Tumor Treating Fields (TTFields) Therapy and Lomustine Chemotherapy for the Treatment of Unresectable Progressive Glioblastoma. (Pubmed Central) - Oct 30, 2024
This patient case is reflective of the EF-14 study outcome using TTFields therapy beyond first progression concomitantly with chemotherapy. The observations from this case suggest that TTFields therapy concomitant with CCNU is a valuable treatment modality in patients with GBM, in this context.
- | lomustine / Generic mfg.
Journal: Prophylactic Antimicrobials for Prevention of Febrile Neutropenia in Tumour-Bearing Dogs Treated With Lomustine. (Pubmed Central) - Oct 28, 2024
Patients with a lower absolute neutrophil count, and a higher VCOG-CTCAE v2 neutropenia grade were also at an increased risk of developing FN (p?=?0.01, p?<?0.001). Additional studies may help establish guidelines for antimicrobial prophylaxis in dogs treated with CCNU, especially for those at high-risk for FN.
- || Avastin (bevacizumab) / Roche, Matulane (procarbazine hydrochloride) / Leadiant Biosci
Review, Journal: The Role of Systemic Therapies in the Treatment of Grades 1-4 Gliomas. (Pubmed Central) - Oct 23, 2024
The beneficial impact of adding chemotherapy to radiotherapy (PCV: procarbazine, lomustine, vincristine) has also been demonstrated. In grade 4 glioblastoma multiforme (GBM), wild-type isocitrate dehydrogenase (IDH) status showed the best treatment outcomes with temozolomide (TMZ) in patients with O-6-methylguanine-DNA methyltransferase (MGMT)
- ||| galunisertib (LY2157299) / Eli Lilly
Trial completion, Monotherapy: A Study in Recurrent Glioblastoma (GB) (clinicaltrials.gov) - Oct 23, 2024
P2, N=151, Completed, Sponsor: Eli Lilly and Company
In grade 4 glioblastoma multiforme (GBM), wild-type isocitrate dehydrogenase (IDH) status showed the best treatment outcomes with temozolomide (TMZ) in patients with O-6-methylguanine-DNA methyltransferase (MGMT) Active, not recruiting --> Completed
- | nimodipine / Generic mfg., vincristine / Generic mfg.
Journal, Tumor cell: Nimodipine Used with Vincristine: Protects Schwann Cells and Neuronal Cells from Vincristine-Induced Cell Death but Increases Tumor Cell Susceptibility. (Pubmed Central) - Oct 16, 2024
There was an opposite change in the protein levels of Ak strain transforming/protein kinase B (AKT) in tumor cells (down) and neuronal cells (up), with simultaneous increased protein levels of cyclic adenosine monophosphate response element-binding protein (CREB) in all cell lines. In the future, this approach may improve tumor response to chemotherapy and reduce unwanted side effects such as neuropathy.
- temozolomide / Generic mfg.
Temozolomide versus PCV chemotherapy in oligodendrogliomas: differences in clinical outcome based on cancer registry data (Studio 3-5) - Oct 13, 2024 - Abstract #DGHO2024DGHO_35;
TMZ chemotherapy was found to be inferior to the PCV regimen in treating OG. Cancer registry data can serve as valuable tools in evaluating treatments for rare tumor entities.
- | lomustine / Generic mfg., temozolomide / Generic mfg.
Journal: Quantitative assessment of residual tumor is a strong and independent predictor of survival in methylated glioblastoma following radiochemotherapy with CCNU/TMZ. (Pubmed Central) - Oct 1, 2024
Low RTV is associated with increased survival in glioblastoma patients undergoing radiochemotherapy with CCNU/TMZ. This study demonstrates the applicability of the recently proposed RANO resect criteria in this subgroup of patients.
- Avastin (bevacizumab) / Roche
Post-progression survival following focal re-irradiation with 20 Gy in 5 fractions in progressive CNS WHO grade 3 astrocytoma and glioblastoma - a monocentric retrospective analysis (Hall 5) - Sep 24, 2024 - Abstract #EANO2024EANO_680;
PFS after Re-RT was 2.6 months, and PPS was 7.6 months, respectively, published data reporting 6-12 months PPS after re-irradiation (EQD2 ranging between 48-60 Gy) despite a comparatively low and conservative cumulative dose of 20 Gy (35 Gy EQD2). Treatment time was only 5 days.
- Keytruda (pembrolizumab) / Merck (MSD)
Shaping the immune landscape - Role of neo(adjuvant) checkpoint inhibition in recurrent glioblastoma (Hall 5) - Sep 24, 2024 - Abstract #EANO2024EANO_656;
Neoadjuvant checkpoint inhibition is well tolerated and associated with distinct changes to tumor transcriptome and immune milieu leading to prolonged overall survival. These findings suggest that the neoadjuvant administration of PD-1 blockade enhances the local and systemic anti-tumor immune response and may represent a more efficient approach to the salvage treatment of this uniformly lethal tumor.
- lomustine / Generic mfg., temozolomide / Generic mfg.
Assessment of response to lomustine-temozolomide chemotherapy in addition to radiotherapy in patients with newly diagnosed glioblastoma using FET PET (Hall 5) - Sep 24, 2024 - Abstract #EANO2024EANO_653;
Our results suggest that FET PET is clinically valuable for identifying responders to lomustine-temozolomide chemotherapy in addition to radiotherapy early after treatment initiation. The evaluation of FET PET
- Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer, Muphoran (fotemustine) / Servier
A novel machine learning (ML) model integrating clinical and molecular data to predict response to second line treatment in recurrent IDHwt-glioblastoma (rGBM) (Hall 5) - Sep 24, 2024 - Abstract #EANO2024EANO_644;
Background: Nitrosoureas (lomustine/fotemustine) and antiangiogenic drugs (bevacizumab or regorafenib) are second-line treatment options for patients with rGBM, but to date predictors of efficacy are lacking. The multi-classification ML model developed in this study was able to identify clinical and molecular signatures of rGBM responding to second-line with bevacizumab or regorafenib or nitrosoureas .This model could be useful to choose the more effective second-line therapy in rGBM patients.
- Torisel (temsirolimus) / Pfizer
Use of biopsy-derived tumor organoids for personalized drug testing in recurrent glioblastoma (Hall 5) - Sep 24, 2024 - Abstract #EANO2024EANO_615;
Association of clinical outcome and MGMT methylation with temozolomide sensitivity corroborated the strength of this approach. Furthermore, patient-individual treatment responses strongly suggest for a future personalized drug testing.
- Stivarga (regorafenib) / Bayer
Drug sensitivity of Recurrent GBM patient-derived organoids correlates with patients (Hall 5) - Sep 24, 2024 - Abstract #EANO2024EANO_556;
Our findings suggest a potential role for NADH-FLIM-based drug response assessment in rGBM-EXP for predicting the efficacy of second-line therapies and improving the overall clinical outcome. Further prospective studies are warranted to validate these findings and potentially guide treatment decisions in clinical practice.
- Stivarga (regorafenib) / Bayer
GBM AGILE Platform trial for newly diagnosed and recurrent GBM: Results of first experimental arm, regorafenib (Lomond Auditorium) - Sep 24, 2024 - Abstract #EANO2024EANO_462;
P2/3
Control is temozolomide (ND) and lomustine (RD). GBM AGILE efficiently and compellingly addressed regorafenib
- dianhydrogalactitol (VAL-083) / Valent Tech
Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma (Alsh) - Sep 24, 2024 - Abstract #EANO2024EANO_423;
P2/3
VAL did not increase OS compared to C in any glioblastoma subtype. GBM AGILE evaluated this agent in less time, at lower cost, & with fewer patients than typical registration trials & is currently evaluating several other arms.
- lomustine / Generic mfg., temozolomide / Generic mfg.
CCNU/TMZ in elderly patients with MGMT-methylated glioblastoma: a multicentric retrospective cohort (Hall 5) - Sep 24, 2024 - Abstract #EANO2024EANO_360;
Combined radiochemotherapy with CCNU/TMZ is feasible in glioblastoma patients aged >70 years, and encouraging survival times were observed. Future prospective analyses involving CCNU/TMZ for MGMT-methylated glioblastoma might consider including elderly patients.
- Avastin (bevacizumab) / Roche
Glioblastoma Research from 1938 to 2021: increased survival, changing treatment regimes, and gender disparities in authorship (Hall 5) - Sep 24, 2024 - Abstract #EANO2024EANO_358;
Almost 100 years of reported survival of patients with glioblastoma document a consistent, but slow increase in survival, with overly optimistic survival reported in non-population-based studies. Research by women as first authors shows an upward trend, although gender equality has not been achieved yet, particularly in last authorship.
- Fibromun (onfekafusp alfa) / Philogen
Unveiling synergistic strategies: CRISPR-guided optimization of L19-TNF immunocytokine therapy in glioblastoma (Hall 5) - Sep 24, 2024 - Abstract #EANO2024EANO_313;
Our research represents a significant step forward in the quest for innovative treatment strategies in glioblastoma. The CRISPR screening under immunotherapeutic selection has revealed a spectrum of synergistic partners and paved the way for a rational design of combinatory treatment approaches to maximize therapeutic efficacy, laying the groundwork for future clinical translation.
- Matulane (procarbazine hydrochloride) / Leadiant Biosci
The APPROACH trial (Analysis of Proton vs Photon Radiotherapy in Oligodendroglioma and Assessment of Cognitive Health): open and recruiting in the UK (Hall 5) - Sep 24, 2024 - Abstract #EANO2024EANO_310;
It aims to evaluate if the dosimetric advantages of PBT translate into clinical or patient benefits regarding NCF, other side effects and HRQoL. Funder: NIHR EME (131082)
- Avastin (bevacizumab) / Roche, Stivarga (regorafenib) / Bayer, Muphoran (fotemustine) / Servier
PTEN alteration as a predictor of second-line efficacy in patients with recurrent IDHwt-glioblastoma (Hall 5) - Sep 24, 2024 - Abstract #EANO2024EANO_228;
We concluded that pathogenic PTEN alteration may be a predictor of poor efficacy of regorafenib and lomustine in rGBM patients. However, a prospective study with a larger population is needed to better define the role of PTEN.
- lomustine / Generic mfg.
EORTC-2227 (LEGATO): Lomustine with and without reirradiation for first progression of glioblastoma: a randomized phase III study (Alsh) - Sep 24, 2024 - Abstract #EANO2024EANO_79;
- | relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
Enrollment open, Trial initiation date: Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma (clinicaltrials.gov) - Sep 20, 2024
P2, N=184, Recruiting, Sponsor: National Cancer Institute (NCI)
However, a prospective study with a larger population is needed to better define the role of PTEN. Not yet recruiting --> Recruiting | Initiation date: Sep 2024 --> May 2025
- | Journal, IO biomarker: Construction and clinical significance of prognostic risk markers based on cancer driver genes in lung adenocarcinoma. (Pubmed Central) - Sep 20, 2024
Not yet recruiting --> Recruiting | Initiation date: Sep 2024 --> May 2025 This study identified 11 effective biomarkers, DE-CDGs, which can predict LUAD prognosis and explored the biological significance of CDGs in LUAD prognosis, immunotherapy, and treatment.
- | temozolomide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Preclinical, Journal: Evaluation of Single and Combined Temozolomide and Doxorubicin Treatment Responses in Low- and High-Grade Glioma In Vitro. (Pubmed Central) - Sep 17, 2024
The current data suggest that both TMZ and DOXO exhibit efficient therapeutic effects on low- and high-grade glioma cells. However, no synergistic effect was observed for combined therapy.
- | lomustine / Generic mfg.
Journal: A two-stage mechanistic reduced-order model of pharmaceutical tablet dissolution: Population balance modeling and tablet wetting functions. (Pubmed Central) - Sep 15, 2024
Specifically, we formulate and fabricate acetaminophen and lomustine solid tablets using different API content and size distributions, characterize their dissolution behavior, and estimate capillary radius as a function of tablet porosity. The estimations generated by the proposed models consistently match the experimental data across all cases investigated in this study.
- | Leukeran (chlorambucil) / GSK
Journal: Case report: Complete clinical remission of feline progressive histiocytosis after multimodal treatment including electrochemotherapy. (Pubmed Central) - Sep 6, 2024
Later on, chlorambucil was also started...In this case report, we describe a successful multimodal therapeutic approach that resulted in complete resolution of the FPH and long-term survival (460?days without external lesions at the time of death). Further studies are necessary to confirm the efficacy of this therapeutic approach.
- | vincristine / Generic mfg.
Journal: Efficacy of vincristine as a rescue therapy for canine histiocytic sarcoma. (Pubmed Central) - Aug 31, 2024
Severe adverse effect was observed in one dog (Grade 3 thrombocytopenia). It is essential to establish novel effective treatments for CHS.
- | Odomzo (sonidegib) / Sun Pharma
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: PersoMed-I: Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (clinicaltrials.gov) - Aug 25, 2024
P2, N=20, Active, not recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
It is essential to establish novel effective treatments for CHS. Recruiting --> Active, not recruiting | N=205 --> 20 | Trial completion date: Mar 2030 --> Apr 2025 | Trial primary completion date: Mar 2030 --> Apr 2025
- Avastin (bevacizumab) / Roche
From Sweet to Sour: A Case of Papaya Leaf Extract Induced Hepatotoxicity (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_3566;
Figure: (A) Aminotransferases, bilirubin and platelet levels graphed over time with corresponding start and stop dates of papaya leaf extract ingestion. (B) Liver biopsy with hematoxylin and eosin stain showing neutrophil predominance and bile duct damage
- | lomustine / Generic mfg.
Retrospective data, Journal: Use of Lomustine and Prednisolone as First-Line Treatment in Canine Multicentric Lymphoma. (Pubmed Central) - Aug 12, 2024
Dogs with multicentric lymphoma treated with lomustine and prednisolone have lower RR, TTP, MDFI and MST compared with dogs receiving multiagent protocols. Based on the short-lasting response, this study confirms that this protocol might have minimal utility beyond palliation.
- | imipramine / Generic mfg., lomustine / Generic mfg.
Trial completion date, Trial primary completion date: Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma (clinicaltrials.gov) - Aug 9, 2024
P2, N=25, Recruiting, Sponsor: The University of Texas Health Science Center at San Antonio
Based on the short-lasting response, this study confirms that this protocol might have minimal utility beyond palliation. Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2024 --> Feb 2026
- ||| sunitinib / Generic mfg.
Clinical, P2/3 data, Journal: The STELLAR trial: a phase II/III randomized trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma. (Pubmed Central) - Aug 8, 2024
To conclude, high-dose intermittent sunitinib treatment failed to improve the outcome of patients with recurrent glioblastoma when compared to standard lomustine therapy. Since lomustine remains a poor standard treatment strategy for glioblastoma, innovative treatment strategies are urgently needed.
- || lomustine / Generic mfg., temozolomide / Generic mfg.
Review, Journal: Current chemotherapy strategies for adults with IDH-wildtype glioblastoma. (Pubmed Central) - Aug 5, 2024
These patients have a lower overall survival rate and less benefit from temozolomide, but there are no better alternatives. Clinical trial participation is encouraged.